Health
Widely prescribed opioid shows minimal pain relief and higher heart risk, study finds
NEWYou can now listen to Fox News articles!
A widely prescribed opioid painkiller showed limited effectiveness and increased risk of negative effects in a new analysis published in BMJ Evidence-Based Medicine.
The study examined tramadol, a common prescription opioid used to treat chronic pain.
Tramadol has historically been perceived as a safer or less addictive opioid, which has contributed to its widespread use in chronic pain treatment, the study authors noted.
PSYCHIATRIST REVEALS HOW SIMPLE MINDSET SHIFTS CAN SIGNIFICANTLY REDUCE CHRONIC PAIN
“Often, we may use tramadol to avoid more addictive drugs like other opioids, though in fact tramadol is a synthetic opioid. It is much milder,” Dr. Marc Siegel, senior medical analyst for Fox News, told Fox News Digital.
In the new analysis, researchers used data from 19 randomized clinical trials involving 6,506 adults with conditions including osteoarthritis, chronic low back pain, neuropathic pain and fibromyalgia. All the studies compared tramadol to a placebo treatment.
The level of pain relief associated with tramadol fell below the threshold typically considered clinically important. (iStock)
Overall, tramadol led to a small decrease in pain, but the amount of relief was less than what is usually considered clinically meaningful, the authors reported.
“It is notable how minimal the pain reduction was and how clearly the study highlighted the elevated risk of serious adverse events, even over relatively short trial durations,” Alopi M. Patel, M.D., pain medicine physician at Icahn School of Medicine at Mt. Sinai in New York City, told Fox News Digital. (Patel was not involved in the study.)
MORE PEOPLE TURN TO ACUPUNCTURE FOR BACK PAIN AS STUDY SHOWS RELIEF
Participants receiving tramadol experienced a higher risk of adverse events, both serious and non-serious, compared with those receiving a placebo.
Serious adverse events primarily included cardiovascular events, such as chest pain, coronary artery disease and congestive heart failure. The authors concluded that tramadol likely increases the risk of heart-related issues.
Serious adverse events were primarily driven by cardiovascular outcomes, including chest pain, coronary artery disease and congestive heart failure. (iStock)
The authors concluded that the benefits of tramadol for chronic pain are small and that the harms likely outweigh the benefits. The findings call into question the use of tramadol for chronic pain conditions, they stated.
Study limitations
Most of the trials included in the analysis were short, with treatment periods ranging from two to 16 weeks and follow-up periods from three to 15 weeks.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
This limited the ability to assess long-term outcomes, the researchers acknowledged.
The authors reported that many outcomes had a high risk of bias, which may have exaggerated the apparent benefits and minimized the reported harms.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The trials involved several different types of chronic pain, but the data were not detailed enough to draw conclusions for any specific condition. This makes it “harder to generalize the findings to specific patient populations,” noted Patel.
Most trials were short in duration and compared tramadol only with a placebo — limiting conclusions about long-term effects and comparisons with other treatments. (iStock)
Though the study has value, Siegel said, “looking at slight increased rates of cancer or heart disease among those on the drug is completely misleading, because it is not controlled for other factors and there is no evidence or hint of causation.”
“You would have to first look at underlying characteristics of that group who took the meds.”
CLICK HERE FOR MORE HEALTH STORIES
The doctor also pointed out that the study “doesn’t compare [tramadol] with full-on opioids like Percocet.”
Experts emphasize that patients should not stop taking tramadol abruptly, as doing so can lead to withdrawal symptoms. Those looking to change their medication should consult a doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“I recommend that clinicians and patients engage in transparent, shared decision-making that considers tramadol’s modest benefits alongside its risks,” Patel advised.
Fox News Digital reached out to several manufacturers of tramadol requesting comment.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial.
Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met its “primary endpoints” of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.
The TroFuse-005 trial is the first global Phase 3 trial to “demonstrate statistically significant improvement” in survival compared to chemotherapy in these patients, according to a Merck press release.
WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS
This was also the first and only antibody-drug conjugate (ADC) to achieve such a result for endometrial cancer patients in this setting, the researchers stated.
An ADC is a targeted cancer therapy that delivers more of the drug to tumor cells while limiting damage to healthy cells.
The investigational drug, sac-TMT, is administered every two weeks via IV infusion. (iStock)
The trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum chemotherapy and immunotherapy.
The patients were randomly assigned sac-TMT, administered every two weeks, or a treatment of the physician’s choice, including doxorubin or paclitaxel chemotherapy. The patients were aware of which treatment they were receiving.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Those receiving sac-TMT showed “clinically meaningful improvement” in their disease state compared to the treatment of physician’s choice, the researchers found.
The study also met response rate benchmarks and exhibited similar side effects to earlier studies of the same drug, Merck reported.
NEW BREAST CANCER DRUG WINS FDA APPROVAL AFTER SLASHING PROGRESSION RISK BY NEARLY 40%
The drugmaker did not disclose any statistics on exact survival benefit, response rate, side effect rates or other details, but the researchers aim to present this Phase 3 data at an upcoming medical meeting.
The drug “may be able to address a critical unmet need for certain patients with advanced endometrial cancer,” said the lead researcher (not pictured). (iStock)
Dr. Domenica Lorusso, the study’s global lead investigator and professor of obstetrics and gynecology at Humanitas University and Humanitas San Pio X in Milan, wrote in a press release that these results show sac-TMT “may be able to address a critical unmet need for certain patients with advanced endometrial cancer, one of the only cancers increasing in both incidence and mortality worldwide.”
CLICK HERE FOR MORE HEALTH STORIES
“Despite recent advances, patients whose disease progresses following treatment with platinum and immunotherapy are urgently in need of new options, and these findings show for the first time that a TROP2 ADC may be an effective option in this setting,” she added.
Dr. Brian Slomovitz, co-director of gynecologic oncology at Mount Sinai and an investigator on this trial, reflected on the study findings during an interview with Fox News Digital.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Unlike many other cancers that we are treating, the number of endometrial cancers and the number of deaths due to endometrial cancers are on the rise,” Slomovitz noted.
“In the United States, the number of deaths due to endometrial cancer has surpassed the number of deaths due to ovarian cancer, [making it] the deadliest of all gynecologic malignancies.”
Endometrial cancer has become “the deadliest of all gynecologic malignancies,” one doctor shared. (iStock)
Despite recent advancements introducing immunotherapy as the standard of care, “better treatment options” for patients with recurrent disease “remains an unmet need,” Slomovitz commented.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“If the full data confirm this announcement, the key questions will be the magnitude of the survival benefit and the toxicity profile — those will define sac-TMT’s role,” he said.
“But an overall survival improvement in recurrent disease is a real, meaningful result for patients and their families, not just a statistical one.”
WHO issues WARNING after DEADLY ebola outbreak
The CDC is coordinating the ‘safe withdrawal’ of at least six Americans exposed to a deadly Ebola outbreak in the Democratic Republic of Congo after the WHO declared a global health emergency.
NEWYou can now listen to Fox News articles!
The World Health Organization has declared an international public health emergency as a growing Ebola outbreak in Central Africa sparks concern that the deadly virus could spread beyond the region — including into the United States.
The outbreak has been linked to dozens of suspected deaths in the Democratic Republic of Congo (DRC) and neighboring Uganda.
Ebola is a zoonotic, viral disease that is rare but life-threatening, according to Cleveland Clinic. Outbreaks typically develop in areas of Africa, starting in species like antelope, fruit bats and nonhuman primates.
WHO HEAD ‘DEEPLY CONCERNED’ OVER ‘SCALE AND SPEED’ OF EBOLA SPREAD, SAYS EMERGENCY COMMITTEE WILL MEET
There are four different Ebola strains, also known as orthoebolaviruses. Bundibugyo virus is the strain that has been detected in the DRC outbreak.
While the outbreak does not meet the criteria for a pandemic emergency, U.S. officials are warning Americans not to visit the area, escalating the State Department travel advisory from a Level 3 to Level 4 on Sunday.
A visitor washes his hands at a checkpoint before entering Kyeshero Hospital in Goma, Democratic Republic of Congo, on May 18, 2026, as part of Ebola prevention measures following a reported case in the city. (Jospin Mwisha/AFP)
One American tested positive for Ebola on May 17 while working in Congo and is being transported to Germany for treatment with other Americans who are high-risk contacts, according to the Centers for Disease Control and Prevention.
As of May 18, there have been 11 confirmed and 336 suspected cases, including 88 deaths in the DRC.
US ISSUES URGENT TRAVEL WARNING AS DEADLY EBOLA OUTBREAK SPREADS OVERSEAS
“This is a rapidly evolving situation, and case counts are subject to change,” the CDC noted.
While no cases have been detected in the U.S., there is a possibility that it could make its way into American territory, posing a threat to public health.
“This virus is transmitted only person-to-person via infected blood and body fluids from symptomatic people.”
Dr. Jacob Glanville, a leading immunologist at Centivax in San Francisco, which is developing a universal flu vaccine, spoke with Fox News Digital about the potential spread of Ebola into the U.S.
The doctor noted that the virus has a two- to 21-day incubation period, during which an infected person can show no symptoms and the infection cannot be detected by tests.
CLICK HERE FOR MORE HEALTH STORIES
“It is thus possible for Ebola to move across international borders silently, bypassing screening,” he said.
“Some travel restrictions from the affected area have been put in place to limit this risk, although as this outbreak was spreading silently for months, it is possible that an infected traveler had come to the U.S. in the past 21 days from the affected areas prior to the travel restrictions.”
A visitor washes his hands at a checkpoint outside Kyeshero Hospital in Goma, Democratic Republic of Congo, on May 18, 2026, as part of Ebola prevention measures following the first reported case in the city. (Jospin Mwisha/AFP)
Glanville noted that while the outbreak is “growing rapidly,” one week ago there were fewer than 500 global cases.
“Thus, the chance of an infected traveler having come to the U.S. remains quite low for the time being,” he said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Dr. Robert H. Hopkins, Jr., medical director of the National Foundation for Infectious Diseases, agreed that the threat to American communities remains low.
“The viruses that cause Ebola pose a very small risk, even to travelers to areas with outbreaks,” the Arkansas-based expert told Fox News Digital. “This virus is transmitted only person-to-person via infected blood and body fluids from symptomatic people, and rarely from infected animals.”
Those who believe they have been exposed to Ebola should seek medical attention immediately, experts advise. (iStock)
Ebola spreads through direct contact with infected blood, bodily fluids or remains of infected people or animals, including fluids such as saliva and sweat, according to Hopkins.
Cleveland Clinic notes that it is “very unlikely” for Ebola to be an airborne infection.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The virus starts with flu-like symptoms, including fever, chills, fatigue, headache, muscle pain, vomiting/diarrhea and loss of appetite. Other signs may include a rash or spots of blood under the skin, hiccups, bruising and red, bloodshot eyes.
As the disease is a type of viral hemorrhagic fever, it causes damage to the blood vessels and can lead to more serious symptoms, including severe bleeding or hemorrhaging, neurological disorders and severe vomiting.
Health workers dressed in protective gear begin their shift at an Ebola treatment center in Beni, Congo, on July 16, 2019. (Jerome Delay/AP)
For those who have traveled to the outbreak area, Hopkins recommends monitoring for symptoms for three weeks after departing and seeking immediate care if symptoms develop.
Treatments are available, along with a vaccine that can help protect high-risk individuals and prevent further spread, according to healthcare professionals.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Avoiding contact with blood, body fluids, and sick or deceased people and animals is “highly effective in the prevention of Ebola transmission,” Hopkins advised.
“If contact is required, high-quality personal protective equipment is recommended before contact with potentially infectious people and/or materials,” he added.
Fox News Digital’s Michael Sinkewicz and Andrea Margolis contributed to this report.
-
Indiana2 minutes agoCaitlin Clark scratched from Indiana Fever lineup at the last minute because of injury
-
Iowa8 minutes agoIowa State AD says he doesn’t care if SEC, Big Ten leave other P4 Conferences behind: ‘Let them break away’
-
Kansas14 minutes agoUnited Market opens in Kansas City’s Linwood Shopping Center, bringing fresh food back to Prospect
-
Kentucky20 minutes agoWATCH: Rep. Thomas Massie’s full concession speech after defeat in Kentucky GOP primary
-
Louisiana26 minutes ago‘A little bit nervous’: Survivor of deadly Mall of Louisiana shooting makes emotional return
-
Maine32 minutes agoMaine’s Memorial Day weekend weather is looking just fine
-
Maryland38 minutes agoTemperature cooldown follows storms in Maryland
-
Michigan44 minutes agoCurt Cignetti Discusses Idea That OSU, Michigan Could Rest Players in Rivalry Game If CFP Expands
